BAX
Baxter International Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$25.83
+1.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.5B | 11.2B | 10.6B | 10.4B | 10.1B |
| Cost of Revenue | 8.0B | 7.9B | 6.7B | 6.2B | 6.5B |
| Gross Profit | 3.5B | 3.4B | 4.0B | 4.2B | 3.5B |
| Operating Expenses | |||||
| R&D Expense | 512.0M | 518.0M | 590.0M | 518.0M | 450.0M |
| SG&A Expense | 2.9B | 2.9B | 3.0B | 3.0B | 3.1B |
| General & Admin Expense | 1.5B | — | 3.0B | 3.9B | 3.1B |
| Selling & Marketing Expense | — | — | — | (985.0M) | — |
| Other Expenses | 280.0M | 279.0M | 413.0M | (28.0M) | 2.8B |
| Total Operating Expenses | 3.7B | 3.7B | 4.0B | 3.4B | 6.4B |
| Cost and Expenses | 11.7B | 11.6B | 10.6B | 9.7B | 12.9B |
| Operating Income (EBIT) | (274.0M) | (308.0M) | 14.0M | 707.0M | (2.8B) |
| Non-Operating | |||||
| Interest Income | 46.0M | 52.0M | 67.0M | 69.0M | 19.0M |
| Interest Expense | 292.0M | 290.0M | 408.0M | 508.0M | 413.0M |
| Net Interest Income | (246.0M) | (238.0M) | (341.0M) | (439.0M) | (394.0M) |
| Other Non-Op Income/Expense | (209.0M) | (197.0M) | (303.0M) | (465.0M) | (403.0M) |
| Non-Operating Income (excl Interest) | (71.0M) | (93.0M) | (105.0M) | (43.0M) | (10.0M) |
| EBT (Pre-Tax Income) | (483.0M) | (505.0M) | (289.0M) | 242.0M | (3.2B) |
| Income Tax Expense | 485.0M | 395.0M | 37.0M | 61.0M | (135.0M) |
| Bottom Line | |||||
| Net Income | (1.1B) | (957.0M) | (649.0M) | 2.7B | (2.4B) |
| Earnings from Cont. Ops | (968.0M) | (900.0M) | (326.0M) | 181.0M | (3.1B) |
| Earnings from Discont. Ops | (95.0M) | (57.0M) | (312.0M) | 2.5B | 692.0M |
| Bottom Line Net Income | (1.1B) | (900.0M) | (649.0M) | 2.7B | (2.4B) |
| Per Share | |||||
| Basic EPS | ($2.04) | ($1.75) | ($1.27) | $5.25 | ($4.83) |
| Diluted EPS | ($2.04) | ($1.75) | ($1.27) | $5.23 | ($4.83) |
| Revenue Per Share | $22.19 | $21.92 | $20.85 | $20.47 | $19.95 |
| Shares | |||||
| Basic Shares Outstanding | 517.0M | 513.0M | 510.0M | 506.0M | 504.0M |
| Diluted Shares Outstanding | 518.0M | 513.0M | 510.0M | 506.0M | 504.0M |
| Profitability Metrics | |||||
| EBITDA | 750.0M | 766.0M | 1.1B | 1.7B | (1.8B) |
| D&A | 953.0M | 981.0M | 997.0M | 984.0M | 1.1B |
| EBIT | (203.0M) | (215.0M) | 119.0M | 750.0M | (2.8B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026